<DOC>
	<DOCNO>NCT01509911</DOCNO>
	<brief_summary>TL-118 anti-angiogenic drug combination design treatment cancer . The investigational product Tl-118 comprise four well-known active component . The therapy administrate unique dose regimen find effective advantageous term safety . The product formulate oral suspension , conveniently administrate patient home require medical staff assistance . This Phase II clinical trial aim evaluate efficacy , safety tolerability TL-118 Gemcitabine treat Pancreatic Cancer patient</brief_summary>
	<brief_title>A Clinical Trial Anti-Angiogenic Drug Combination Tl-118 Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Age least 18 year enrollment . 2 . Metastatic Pancreatic Cancer 3 . The patient histologically cytologically confirm pancreatic adenocarcinoma . 4 . Patient measurable disease ( RECIST ) . 5 . Patient start standard care Gemcitabine treatment 6 . ECOG performance status â‰¤ 1 7 . Adequate renal function 8 . Adequate hepatic function 9 . Adequate bone marrow reserve 10 . Resolution prior therapy acute adverse event . 11 . Patient capable swallowing . 12 . Patient 's Informed Consent . 1 . Hypersensitivity one TL118 active component 2 . Known Glucose6phosphatedehydrogenase deficiency ( G6PD ) . 3 . CNS Brain metastases 4 . Prior systemic therapy pancreas cancer 5 . Subjects receive investigational medication , prior local therapy pancreas cancer , significant change treatment within 1 month prior screen 6 . Concurrent use investigational product 7 . Subjects clinically significant unstable medical condition would preclude safe complete study participation 8 . Use supplement complementary medicines/botanicals , except conventional multivitamin supplement , calcium , selenium soy supplement . 9 . Patient known historical active infection HIV , hepatitis B , hepatitis C 10 . Circumstances likely interfere absorption orally administrate drug . 11 . History noncompliance medical regimen coexist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>